Your Article Summary
See Latest ArticlesTeva receives first u.s. approval for generic pulmicort respules; commences commercial launch
Teva Pharmaceutical Industries, 11/20/08
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca's Pulmicort (Budesonide) Respules, 0.25 mg/2 mL and 0.5 mg/2 mL indicated for twice daily treatment of Asthma. Shipment of these products has commenced.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09